Cladribine Effectiveness After Switching from DMTs - A Nationwide Danish Study

Evidence for the effectiveness of cladribine as a switch therapy from high-efficacy disease-modifying treatments in relapsing-remitting MS is limited. At ECTRIMS 2025, Shanga Hassan Qadir from the Danish Multiple Sclerosis Registry at Copenhagen University Hospital presented a nationwide, real-world Danish cohort study evaluating cladribine’s ability to maintain disease stability after switching from other high-efficacy therapies. In this MEDtalk, the key study findings and clinical data are presented.